An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the reveal registry

Chest

Volumn 142, Issue 2, 2012, Pages 448-456

  Benza, Raymond L ^a   Miller, Dave P ^b   Barst, Robyn J ^c   Badesch, David B ^d   Frost, Adaani E ^e   McGoon, Michael D ^f  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b ICON Late Phase and Outcomes Research   (United States)

^c Columbia University College of Physicians and Surgeons ^*  (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE;

ARTICLE; COHORT ANALYSIS; DISEASE REGISTRY; FEMALE; HEART CATHETERIZATION; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH PROGNOSTIC EQUATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; SCORING SYSTEM; SURVIVAL PREDICTION; SURVIVAL RATE; UNITED STATES;

EID: 84863519076     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-1460     Document Type: Article

References (20)

1. McGoon MD, Kane GC; . Pulmonary hypertension: diagnosis and management,. Mayo Clin Proc. 2009; 84(2): 191-207.
2. McLaughlin VV, Archer SL, Badesch DB; et al. ; ACCF/AHA. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association,. Circulation. 2009; 119(16): 2250-2294.
3. D'Alonzo GE, Barst RJ, Ayres SM; et al. . Survival in patients with primary pulmonary hypertension. Results from a national prospective registry,. Ann Intern Med. 1991; 115(5): 343-349.
4. Rich S, Dantzker DR, Ayres SM; et al. . Primary pulmonary hypertension. A national prospective study,. Ann Intern Med. 1987; 107(2): 216-223.
5. Humbert M, Sitbon O, Chaouat A; et al. . Pulmonary arterial hypertension in France: results from a national registry,. Am J Respir Crit Care Med. 2006; 173(9): 1023-1030.
6. Humbert M, Sitbon O, Chaouat A; et al. . Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era,. Circulation. 2010; 122(2): 156-163.
7. Jing ZC, Xu XQ, Han ZY; et al. . Registry and survival study in Chinese patients with idiopathic and familial pulmonary arterial hypertension,. Chest. 2007; 132(2): 373-379.
8. Nunes H, Humbert M, Sitbon O; et al. . Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension,. Am J Respir Crit Care Med. 2003; 167(10): 1433-1439.
9. Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg-Maitland M; . Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation,. Eur Respir J. 2010; 35(5): 1079-1087.
10. McGoon MD, Krichman A, Farber HW; et al. . Design of the REVEAL registry for US patients with pulmonary arterial hypertension,. Mayo Clin Proc. 2008; 83(8): 923-931.
11. Benza RL, Miller DP, Gomberg-Maitland M; et al. . Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL),. Circulation. 2010; 122(2): 164-172.
12. Simonneau G, Galiè N, Rubin LJ; et al. . Clinical classification of pulmonary hypertension,. J Am Coll Cardiol. 2004; 43(12suppl S): 5S-12S.
13. Badesch DB, Raskob GE, Elliott CG; et al. . Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry,. Chest. 2010; 137(2): 376-387.
14. Suissa S; . Immortal time bias in observational studies of drug effects,. Pharmacoepidemiol Drug Saf. 2007; 16(3): 241-249.
15. Tsai W, Jewell N, Wang M; . A note on the product-limit estimator under right censoring and left truncation,. Biometrika. 1987; 74(4): 883-886.
16. Keiding N; . Independent delayed entry,. In: Klein JP, Goel PK; , eds. Survival Analysis: State of the Art. Dordrecht, Netherlands: Kluwer Academic Publishing; 1992: 309-326.
17. Stuart E, Cole S, Bradshaw C, Leaf P;. The use of propensity scores to assess the generalizability of results fromrandomized trials (May 2010),. Johns Hopkins University, Dept. of Biostatistics Working Papers. Working Paper 210. Berkeley Electronic Press website. http://www.bepress.com/jhubiostat/paper210. Accessed November 30, 2011.
18. Frost AE, Badesch DB, Barst RJ; et al. . The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries,. Chest. 2011; 139(1): 128-137.
19. Kane GC, Maradit-Kremers H, Slusser JP, Scott CG, Frantz RP, McGoon MD; . Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension,. Chest. 2011; 139(6): 1285-1293.
20. Humbert M, Sitbon O, Yaïci A; et al. ; French Pulmonary Arterial Hypertension Network. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension,. Eur Respir J. 2010; 36(3): 549-555.